Drugs / Tabirafusp tedromer
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06556368 | Aug 2024 → Aug 2026 overdue | wet macular degeneration | Kodiak Sciences Inc | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tabirafusp tedromer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556368 ↗ |
| Route | Intravitreal | “Intravitreal injection” NCT06556368 ↗ |